Member Info for CuriousInvester6

Unfortunately Solow it is the nature of any new start company...in 6 years the company has had some new major shareholders, new investors, new CEO plus plus Excecutive team and advisors that are at the top of their profession. Looking back is not really relevant now. What we do know is that there is a working system generating 52 Mev in Geneva which I understand from sources can not be increased in Geneva due to the size of the property. This is why integration is progressing at Daresbury. We know through previous RNS & analyst reports that adding additional CCL's is proven technology by CERN who are world leaders in linear accelerators. That is why reports all say the project has been somewhat de-risked.
There is always a risk and much fine tuning will be required, I sincerely hope it will be successful and as PM44 has highlighted the rewards will be very high. Hope this helps and GLA

Munners: 190 Mev would be suitable for most treatments...I would expect Daresbury to be at that level when approx 3 more CCL's are delivered and positioned. It would seem looking at the upcoming timelines this progress could be reported in the 4th quarter along with other milestones which would be good for price momentum.

https://www.avoplc.com/Portals/0/Documents/Investor%20Relations/General%20Meetings/AGM%20Presentation.pdf

Interesting comparisons with the UCL site, clearly LIGHT will be extremley disruptive technology.

The presentation inlcudes details of the Geneva sites, Daresbury site and more photos of Harley Street

Does anyone have any observations from the meeting?

Solow..you are correct looking at March 2017 Timeline, but this was revised in March 2018 and a great deal has progressed since then with new major shareholders and capital etc. Unless you are shorting this stock I believe in the scheme of things even if there are some delays this is a pretty good update!

I believe the linear technology has already been validated by CERN if you read all the Analyst reports going back at least to 2017. The hardest part was getting to 52Mev and thereafter it is down to integrating the CCL's which are similar structures as have been previously proven. To be fair to the company the Technical update today confirms thr Timeline as per presented in March 2018.is on track. I am somewhat relieved!!!

I would refer you to the Harman & Co report March 2018 (4th Qtr ) and March 2017 (3rd Qtr) Timeline. First patient was always H2 2020. With disruptive new technology I really dont think minor delays are to be concerned about and the company has always said H2 2020 as far as I have followed them.

Everything looks to be well organised and on track!

https://polaris.brighterir.com/public/advanced_oncotherapy/news/rns/story/w93z4dw

Agreed, the timeline presented March last year shows regulatory and clinical acceptance to be Q2 & Q3 2020 leading to 1st Patient Treatment Q4 2020. I would hope on confirmation of technical progress and with additional CCL'S being manufactured and delivered for testing at Daresbury we will see a steady improvement in the share price. Maybe tomorrow attendees at the AGM can post any updates.

Unless you have other information it depends what you mean as fully functional as technically the sysytem was fully function when LIGHT achieved 52 Mev in Geneva, since then the company advised as indeed it is in the time line that components have been sent to the assembley site Daresbury for integration and testing.

I think the confusion lies within the term 'fully functional', I share your concerns but it does seem that to reach 230Mev a number of CCL's have to be delivered to Daresbury and as highlighted in the Goetzpartners note these are obviously being delivered over the later part of this year "which will enable the company to generate a proton beam with sufficient energy to treat deep-seated tumours following full integration."

What I we would all like to know is at what stage are we and how many CCL's have been delivered.

Overall though the most important milestones is the H2/2020 first treatment and with the Harley Street fit out started the company appears to be on track.

https://www.avoplc.com/Portals/0/Documents/Investor%20Relations/Broker%20Notes/FY2018%20results%20reflect%20operational%20progress.PDF

" With the development timeline on schedule and first patients due to be treatedin H2/2020E, we believe that AVO offers strong upside potential. We maintain both ourOUTPERFORM recommendation and £1.55 TP."

Good to see some nice buys this morning, certainly looked to me to have been oversold the last few days. As far as I am aware everything is still on track as confirmed in the 3rd June RNS unless we hear otherwise. Too many big investors supporting this company for any adverse news not to have been released to the market!

I agree with your action Wallace4, without a further tech update this week I fear the share will reduce significantly further.

RNS 3rd June 2019: "We have important milestones ahead of us, including our first site in Harley Street which we expect to be soon ready for fit-out, and we reiterate our commitment to treat our first patients towards the end of 2020."
So todays RNS confirming Harley Street on time and to budget....now all we want is a positive tech update and any additional positive news on Thursday!

The important line from the RNS to me is " which has been delivered on time and to budget"
However the point you make about "expected" could perhaps mean that there is another site being prepared which could well accept the first LIGHT system prior to end 2020?
The opening paragraph still says: "the site of the Company's first proposed commercial installation of its proton-based radiotherapy system, has been completed." Again perhaps as the first propsed commercial installation may not now mean the first installation.
Whatever nothing negative in the RNS as far as I can see but it does open up some very interesting questions which I dare say will be answered on Thursday this week!

I had to re read the Final YE Report...these I believe are the critical two paragraphs:

"In October 2018, we were proud to announce that LIGHT was able to generate a proton beam with an energy of 52MeV, roughly double theoutput energy achieved a month earlier, and sufficient to treat superficial tumours such as ocular tumours, parotid gland tumours, basalcell carcinoma, and some soft tissue sarcomas, to name a few. The development team remains focussed on the lower-execution riskactivity of adding further accelerating modules, which have the same designs as the ones already tested and operating, and with thesuccessful integration of a total of 15 accelerating modules the LIGHT systems will generate a proton beam of 230MeV, the energy requiredfor the effective treatment of deep-seated tumours."

"We have been encouraged by the successful ongoing testing of our Time-of-Flight measurement system which measures the speed of thebeam and allows the evaluation of the energy of each proton pulse, an important clinical parameter, key for ensuring beam control andadjustability."

I guess it would have been good to have had a regular progress report on the Time-of Flight measurements

Oh dear looks like momentum is being lost...unfortunately everything is too slow, no regular updates regarding the technology since October 2018 and what progress has been made toward achieving 230Mev. Such a shame as leading up to the AGM would have been nice to see a nice rally.

I think we are talking cross purposes. When you say getting the system up and running I interpretted this to be treating first patients which has been 2020 for a couple of years. So apologies, however I believe you are refering now to the asssembly of the complete line at Daresbury which you are correct we do not know if that has been completed although the Final Results statement says; "Preparations at the Science and Technology Facilities Council ("STFC") Daresbury Laboratory are proceeding to plan with the continued commitment of treating first patients by the end of 2020."

I guess we will know the status of the plan at the AGM. It is probably therefore premature to second guess this.

With regard to the 'building works' it appears these have been completed or nearing completion and importantly to plan as the company also mentions that they are now "shortly moving into fit-out phase and we expect to have all of the accelerating modules manufactured later this year" they go on to say "By the end of the year, we aim to have a tailor made treatment plan in place for our LIGHT system and expect to have the entire patient positioning system installed"

I hope that the treatment of first patients in 2020 does not change although of course there may well be legitmate reasons in the future if it does change.

The share price reduction today may well be indicative of other shareholders sharing your views. For me if the price comes off anymore I will be buying more!

This is not correct it was always treating first patients in 2020. The company provided shareholders a time line that also included a very specific build programme and time line for Harley Street where the first LIGHT system will be installed.

Although I read everything is on track I am dissapointed that no progress seems to have been made since 52Mev was announced in Oct 2018.

"We have fullyintegrated all key accelerating components and achieved the most challenging aspect of generating a beam with an energy level capable of treating superficial tumours.Page 2 of 6
In October 2018, we were proud to announce that LIGHT was able to generate a proton beam with an energy of 52MeV"

https://polaris.brighterir.com/public/advanced_oncotherapy/news/rns/story/r71vm7r/export

Annual General Meeting to be held at 2pm on Thursday, 25 July 2019 at the Royal Society of Medicine, 1 Wimpole Street, London W1G 0AE.